Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology ...

Bayer initiates phase II panSOHO study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumours: Berlin Wednesday, March 5, 2025, 09:00 Hrs [IST] Bayer announced t ...

Researchers developed the 24-hour dietary recall–plastic exposure (24DR-PE) tool to assess and quantify dietary plastic ...

Researchers associated with the New York-based Memorial Sloan Kettering Cancer Center have obtained positive results in the ...

"Generative AI is prone to produce hallucinations, and incorporating physics-based elements is a key approach to reducing them," commented CASUS. "As the AI-based quantitative phase imaging example ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...

The nonprofit’s stem cell therapy was able to completely restore the cornea in one of the 14 patients on the Phase I/II trial ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...

Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all ...

A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...